Want to join the conversation?
Barclays analyst Jay Gelb asks about the potential magnitude of the 3Q16 actuarial assumption review. $MET says that it accelerated the economic assumption review & the risk margin review for the VA business. The other reviews done on mortality and morbidity will have to wait until the company gets there. But history-wise, those tend to be modest.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?